TeklaLife Sciences Investors (HQL) Key Ratios

Stock Card

$20.64

$-0.07 (-0.34%)

As on 04-Sep-2026 16:00EDT

Market cap

$638 Mln

Revenue (TTM)

$-- Mln

P/E Ratio

3.1

P/B Ratio

1.1

Div. Yield

9.1 %

Key Ratios and Highlights

Growth Score (%)	Quarterly		Annual (TTM)
Particulars	QoQ	YoY	1-Year	3-Years	5-Years
Revenue	--	164.14	-0.35	41.56	-6.99
EBIT	--	--	--	--	--
Net Profit	--	238.33	0.35	41.25	-7.00
EPS	--	231.35	0.00	39.72	-10.57
Book Value	--	--	11.35	4.71	-2.66

Key Ratios (%)	Average		Annual (TTM)
Particulars	3-Years	5-Years	Sep-25	Sep-24	Sep-23
EBIT-Margin	96.71	98.24	--	98.40	95.02
Net Margin	--	--	--	--	--
Return on equity	14.33	6.62	17.59	19.80	5.59
Return on Capital	14.30	6.66	17.59	19.80	5.51
Return on Assets	14.26	6.68	17.54	19.76	5.47
Debt to Equity (x)	--	--	--	--	--

Profitability

View Detailed Peer Comparison

ROCE

17.59

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	17.59	19.80	5.51	-22.40	12.80
Peer Median	--	--	--	--	--

ROE

17.59

Profit after tax / Average Net worth * 100

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	17.59	19.80	5.59	-22.71	12.82
Peer Median	--	--	--	--	--

ROA

17.54

Profit after tax / Average Total assets * 100

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	17.54	19.76	5.47	-22.05	12.67
Peer Median	--	--	--	--	--

EBIT Margin

Operating profit (EBIT) / Net Sales * 100

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	98.40	95.02	101.31	98.24
Peer Median	--	--	--	--	--

Net Margin

99.08

Net profit / Total Income (Net sales plus other income) * 100

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	99.08	98.40	95.02	101.31	98.24
Peer Median	--	--	--	--	--

Growth

View Detailed Peer Comparison

Revenue Growth

0.00

Year on year growth in net sales

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	0.00	2.69	1.23	-2.57	-0.47
Peer Median	--	--	--	--	--

EBIT Growth

Year on year growth in operating profit (EBIT)

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	281.60	121.37	-262.10	-47.56
Peer Median	--	--	--	--	--

Net Profit Growth

0.35

Year on year growth in profit after tax

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	0.35	281.60	121.37	-262.10	-47.56
Peer Median	--	--	--	--	--

EPS Growth

0.00

Year on year growth in earnings per share

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	0.00	2.55	1.20	-2.56	-0.50
Peer Median	--	--	--	--	--

Solvency

View Detailed Peer Comparison

Debt to Equity

Total debt / Net worth

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	--	--	0.03	0.00
Peer Median	--	--	--	--	--

Short term debt to equity ratio

(Short term borrowings / Net worth)

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	--	--	0.03	0.02
Peer Median	--	--	--	--	--

Current Ratio

1.74

Current Assets / Current Liabilities and Provisions

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	1.74	0.32	--	0.12	0.01
Peer Median	--	--	--	--	--

Quick Ratio

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	--	--	-6.46	-1.60
Peer Median	--	--	--	--	--

Interest Coverage

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	--	--	--	--
Peer Median	--	--	--	--	--

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

1.32

Debtors outstanding / Net Sales * 100

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	1.32	0.27	21.44	-0.60	0.23
Peer Median	--	--	--	--	--

Asset Turnover

0.18

Sales / Average Total Assets

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	0.18	0.20	0.06	-0.22	0.13
Peer Median	--	--	--	--	--

Receivable days

2.89

Average Debtors / Sales * 365

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	2.89	11.11	44.00	-1.37	0.62
Peer Median	--	--	--	--	--

Inventory Days

Average Inventory / Sales * 365

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	1,383.15	1,875.53	1,674.70	1,128.92
Peer Median	--	--	--	--	--

Payable days

26.55

Average Creditors / Cost of goods sold * 365

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	26.55	0.12	355.20	172.79	9.80
Peer Median	--	--	--	--	--

Cash Conversion Cycle

Receivable Days + Inventory Days - Payable Days

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	--	1,394.14	1,564.34	1,500.55	1,119.74
Peer Median	--	--	--	--	--

Valuation

View Detailed Peer Comparison

Price / Earnings

5.23

Current share price divided by earning per share in the last twelve months

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	5.23	5.09	14.95	-3.35	7.95
Peer Median	--	--	--	--	--

Price / Book Value

0.87

Current share price divided by book value per share in the latest financial year

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	0.87	0.94	0.83	0.88	0.98
Peer Median	--	--	--	--	--

EV/EBITDA

5.23

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name	Sep-25	Sep-24	Sep-23	Sep-22	Sep-21
TeklaLife Sciences Investors (HQL)	5.23	4.78	14.26	-3.14	7.71
Peer Median	--	--	--	--	--

Annual
Quarterly